The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Disruption of the eIF4F translation initiation complex as a determinant of diffuse large B-cell lymphoma responsiveness to enzastaurin (LY317615.HCl) and its primary metabolite (LY326020).
Jeremy Richard Graff
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ann M McNulty
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Chad A Dumstorf
Employment or Leadership Position - Lilly
Stephen H Parsons
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Bruce W Konicek
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Chad A Hall
Employment or Leadership Position - Lilly